Vir Biotechnology, Inc.
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
About Vir Biotechnology
Biological Products, (No Diagnostic Substances), SIC 2836
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for serious infectious diseases and cancer. The company utilizes proprietary artificial intelligence antibody engineering and masked T-cell engager platforms to create treatments that enhance immune responses against life-threatening illnesses. Its clinical pipeline includes investigational therapies for chronic hepatitis delta, specifically the combination of tobevibart and elebsiran, as well as T-cell engagers targeting solid tumors, including metastatic castration-resistant prostate cancer, HER2-expressing cancers, and EGFR-expressing cancers. Vir Bio also researches preclinical antibody candidates for HIV, influenza, and coronaviruses. The company targets patients suffering from severe medical conditions with limited therapeutic options, collaborating with global health foundations and commercial biopharmaceutical partners.
The company conducts clinical trials and establishes international licensing arrangements across various regions, including the United States, Europe, Australia, New Zealand, and Greater China. Vir Bio maintains internal process and analytical development facilities while utilizing external contract development and manufacturing organizations to advance its pipeline. The company's headquarters are not stated in the provided text.
Summary of the business section of Vir Biotechnology's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vir Biotechnology, Inc.
- Founded
- 2016
- Headquarters
- San Francisco, CA
- Address
- 1800 Owens Street, Suite 900 94158
- Phone
- (415) 906-4324
- Website
- www.vir.bio
- Employees
- 367, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- VIR
- Exchange
- Nasdaq
- IPO date
- Oct 11, 2019
- Shares outstanding
- 169M, Jul 29, 2026
- Public float
- $689.20M, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1706431
- CUSIP
- 92764N102
- ISIN
- US92764N1028
- EIN
- 81-2730369
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Backer Marianne De | President and CEO, Director | 1,001,263 |
| Brent Sabatini | SVP, Chief Accounting Officer | 61,902 |
| Jason O'Byrne | EVP & Chief Financial Officer | 162,615 |
| Mark Eisner | EVP and Chief Medical Officer | 154,024 |
| Verneuil Vanina de | EVP, General Counsel, Corp Sec | 112,982 |
| Ann M. Hanly | EVP & Chief Technology Officer | 117,913 |
| Robert J. More | Director | 558,573 |
| Timothy Coughlin | Director | 0 |
| Janet Napolitano | Director | 21,216 |
| Charles Elliott Sigal | Director | 49,806 |
| Norbert W. Bischofberger | Director | 32,000 |
| Jeffrey S. Hatfield | Director | 39,806 |
| Ramy Farid | Director | 32,000 |
| Vicki L. Sato | Director | 1,078,391 |
| Saira Ramasastry | Director | 22,619 |
| George A. Scangos | Director | 1,849,969 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $7.83M | $3.10M | $2.00M | $23 | $125 |
| FY2025 Dr.De Backer | $7.83M | $3.10M | $2.00M | $23 | $125 |
| FY2024 | $9.26M | $3.99M | $1.90M | $27 | $93 |
| FY2024 Dr.De Backer | $9.26M | $3.99M | $1.90M | $27 | $93 |
| FY2024 Dr.Scangos | $0 | $0 | $1.90M | $27 | $93 |
| FY2023 Dr De Backer | $39.49M | $18.21M | $3.53M | $38 | $94 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 367 employees, 282 of whom were primarily engaged in research and development activities.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 10, 2024 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Oct 11, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 9, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |